W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach
{"title":"在dezaparvovec基因治疗B型血友病的3期HOPE-B试验中,携带和不携带腺相关病毒血清5型中和抗体(滴度<1:700)的个体的出血保护持久性和因子IX活性","authors":"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach","doi":"10.1055/s-0042-1760524","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":217767,"journal":{"name":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B\",\"authors\":\"W. S. Pipe, WG F Leebeek, M. Recht, S. Key, S. Lattimore, G. Castaman, D. Cooper, S. Verweij, R. Dolmetsch, J. Tarrant, Y. Li, E. P. Monahan, W. Miesbach\",\"doi\":\"10.1055/s-0042-1760524\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":217767,\"journal\":{\"name\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"volume\":\"57 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1055/s-0042-1760524\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0042-1760524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Durability of bleeding protection and Factor IX activity in individuals with and without adeno-associated virus serotype 5 neutralising antibodies (Titres <1:700) in the phase 3 HOPE-B trial of etranacogene dezaparvovec gene therapy for haemophilia B